Resveratrol and its derivates improve inflammatory bowel disease by targeting gut microbiota and inflammatory signaling pathways

被引:25
|
作者
Li, Ming [1 ]
Li, Ping [1 ]
Tang, Rongxue [1 ]
Lu, Hui [1 ]
机构
[1] Nanchang Univ, State Key Lab Food Sci & Technol, Nanchang 330047, Jiangxi, Peoples R China
关键词
Resveratrol; Inflammatory bowel disease; Intestinal barrier; Gut microbiota; Inflammatory signaling pathways; KAPPA-B ACTIVATION; DIETARY RESVERATROL; ULCERATIVE-COLITIS; TRANS-RESVERATROL; DOUBLE-BLIND; METABOLISM; SUPPLEMENTATION; ANTIOXIDANT; APOPTOSIS; THERAPY;
D O I
10.1016/j.fshw.2021.07.003
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
Inflammatory bowel disease (IBD) is a chronic inflammatory lesion of the intestine, mainly manifested by infiltration of intestinal inflammatory cells and imbalance of gut microbiota. Conventional treatments for IBD include antibiotics, immunosuppressive agents, 5-aminosalicylic acid, steroids and surgery, which have high toxic side effects. Resveratrol is a natural polyphenol, and its various derivatives have anti-oxidation and anti-inflammatory properties. In this paper, we comprehensively review the mechanism of resveratrol and its derivates to alleviate IBD by improving intestinal barrier, regulating the unbalanced gut microbiota, and targeting various inflammatory signaling pathways. (C) 2021 Beijing Academy of Food Sciences. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co, Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:22 / 31
页数:10
相关论文
共 50 条
  • [41] Gut microbiota and inflammatory bowel disease:The current status and perspectives
    Lie Zheng
    Xin-Li Wen
    World Journal of Clinical Cases, 2021, 9 (02) : 321 - 333
  • [42] Cellular Stress Responses and Gut Microbiota in Inflammatory Bowel Disease
    Cao, Siyan Stewart
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2018, 2018
  • [43] Gut microbiota therapy improves outcomes in inflammatory bowel disease
    Qi, G.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I2364 - I2364
  • [44] Gut microbiota in inflammatory bowel disease: a target for therapy not to be missed
    Larussa, Tiziana
    Abenavoli, Ludovico
    Fabiano, Giulia
    Mancuso, Maria A.
    Polimeni, Natale
    Dumitrascu, Dan L.
    Luzza, Francesco
    MINERVA GASTROENTEROLOGY, 2021, 67 (04): : 357 - 368
  • [45] Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease
    Pandey, Himani
    Jain, Dheeraj
    Tang, Daryl W. T.
    Wong, Sunny H.
    Lal, Devi
    INTESTINAL RESEARCH, 2024, 22 (01) : 15 - 43
  • [46] Immune response to gut fungal microbiota in inflammatory bowel disease
    Galanova, N.
    Bajer, L.
    Coufal, S.
    Vancikova, S.
    Kostovcik, M.
    Jackova, Z.
    Reiss, Z.
    Vavreckova, M.
    Zakostelska, Jiraskova Z.
    Drastich, P.
    Tlaskalova-Hogenova, H.
    Kverka, M.
    Kostovcikova, K.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2022, 52 : 58 - 58
  • [47] The gut microbiota during biological therapy for inflammatory bowel disease
    Caenepeel, C.
    Viera-Silva, S.
    Verstockt, B.
    Machiels, K.
    Davani, N. A.
    Sabino, J.
    Ferrante, M.
    Raes, J.
    Vermeire, S.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S016 - S018
  • [48] Gut Fungal Microbiota: The Yin and Yang of Inflammatory Bowel Disease
    Richard, Mathias L.
    Lamas, Bruno
    Liguori, Giuseppina
    Hoffmann, Thomas W.
    Sokol, Harry
    INFLAMMATORY BOWEL DISEASES, 2015, 21 (03) : 656 - 665
  • [49] Gut microbiota in patients with Inflammatory Bowel Disease during remission
    Pisani, A.
    Rausch, P.
    Ellul, S.
    Bang, C.
    Tabone, T.
    Cordina, C. Marantidis
    Zahra, G.
    Ellul, P.
    Franke, A.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S604 - S605
  • [50] Gut microbiota and inflammatory bowel disease: The current status and perspectives
    Zheng, Lie
    Wen, Xin-Li
    WORLD JOURNAL OF CLINICAL CASES, 2021, 9 (02) : 321 - 333